VR Adviser’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,474,485
| Closed | -$130M | – | 35 |
|
|
2026
Q1 | $130M | Sell |
6,474,485
-254,500
| -4% | -$4.1M | 4.86% | 5 |
|
|
2025
Q4 | $109M | Hold |
6,728,985
| – | – | 5.37% | 5 |
|
|
2025
Q3 | $82M | Hold |
6,728,985
| – | – | 4.61% | 6 |
|
|
2025
Q2 | $76.1M | Buy |
6,728,985
+25,000
| +0.4% | +$306K | 5.7% | 5 |
|
|
2025
Q1 | $77.4M | Buy |
6,703,985
+454,254
| +7% | +$4.64M | 6.58% | 5 |
|
|
2024
Q4 | $52.9M | Hold |
6,249,731
| – | – | 3.63% | 9 |
|
|
2024
Q3 | $72.4M | Hold |
6,249,731
| – | – | 3.79% | 9 |
|
|
2024
Q2 | $73.6M | Hold |
6,249,731
| – | – | 4.69% | 7 |
|
|
2024
Q1 | $74.1M | Buy |
6,249,731
+2,157,000
| +53% | +$28.8M | 3.53% | 7 |
|
|
2023
Q4 | $50.1M | Buy |
4,092,731
+1,176,064
| +40% | +$10.7M | 3.44% | 9 |
|
|
2023
Q3 | $28.1M | Hold |
2,916,667
| – | – | 2.96% | 11 |
|
|
2023
Q2 | $26.3M | Hold |
2,916,667
| – | – | 4.2% | 8 |
|
|
2023
Q1 | $22.9M | Hold |
2,916,667
| – | – | 4.48% | 9 |
|
|
2022
Q4 | $19.7M | Buy |
+2,916,667
| New | +$15.6M | 3.32% | 11 |
|
Other funds holding KALV
VR Adviser's KALV Position: Q2 2026 in Review
VR Adviser sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 6,474,485 shares — an estimated $130M sold.
VR Adviser first reported a position in KALV in Q4 2022 and held it in 14 quarters. The position peaked at $130M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- VR Adviser reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- VR Adviser sold 6,474,485 KalVista Pharmaceuticals shares in Q2 2026, an estimated $130M.
- VR Adviser first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 14 quarters.
- VR Adviser's KalVista Pharmaceuticals position peaked at $130M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.